We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Gene Variants Predict Child Neuroblastoma Risk

By LabMedica International staff writers
Posted on 02 Oct 2017
Print article
Image: A photomicrograph of a typical neuroblastoma with rosette formation (Photo courtesy of the U.S. National Cancer Institute).
Image: A photomicrograph of a typical neuroblastoma with rosette formation (Photo courtesy of the U.S. National Cancer Institute).
Potential biomarkers predicting a child's risk for developing neuroblastoma are linked to common variants in the MMP20 (matrix metalloproteinase-20) gene on chromosome 11q.

Investigators at Children's Hospital of Philadelphia (PA, USA) used a genome-wide association study (GWAS) to identify common variants at chromosome locus 11q22.2 within MMP20 that associated with neuroblastoma cases harboring an 11q deletion in 113 European-American cases and 5109 ancestry-matched controls. The association was replicated in 44 independent cases and 1902 controls.

"These inherited variants predispose to 11q deletions, which are a strong risk factor," said Dr. Hakon Hakonarson, director of the center for applied genomics at Children's Hospital of Philadelphia.

"We already knew that 11q deletions are biomarkers that predict poor outcomes in neuroblastoma," said contributing author Dr. John M. Maris, pediatric oncologist at Children's Hospital of Philadelphia. "This new research helps us to more precisely predict how a neuroblastoma tumor will behave, so it improves our diagnostic capabilities."

The study was published in the September 18, 2017, online edition of the journal Nature Communications.

Related Links:
Children's Hospital of Philadelphia

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The Sampler device could revolutionize sample collection for diagnostic tests (Photo courtesy of ReadyGo Diagnostics)

First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.